Dyno signs second Roche deal worth over $1B
George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...
Keep Talking Greece2h
Greece lifts “protection status” of witnesses to NOVARTIS case
The Financial Prosecutor’s Office has decided to lift the protection status of witnesses in a bribery case involving Swiss pharmaceutical giant Novartis, doctors and public officials following ...
Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of Novartis (NVS) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for ...
Novartis ribociclib recognized as Category 1 treatment by NCCN Guidelines
This month, the NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines, for breast cancer were updated to recommend ribociclib as a ...
3 Absurdly Cheap Stocks That Pay High Dividends
Three absurdly cheap dividend stocks that are trading at modest multiples of their expected earnings today are Merck ( MRK -0 ...
The Financial Express10h
NCCN Guidelines recognises Novartis’ ribociclib as Category 1 preferred breast cancer adjuvant treatment
In addition to the recent FDA approval of Kisqali for EBC patients in the US and CHMP positive opinion in Europe, regulatory ...
Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN)
In a report released on October 22, David Evans from Kepler Capital maintained a Buy rating on Novartis AG (NOVN – Research Report), ...